{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:33:48Z","timestamp":1789612428749,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116824","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:18:13Z","timestamp":1779466693000},"page":"116824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lenvatinib plus pembrolizumab versus standard of care in recurrent\/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-0288","authenticated-orcid":false,"given":"Hye Ryun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-8130","authenticated-orcid":false,"given":"Marc","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-9074","authenticated-orcid":false,"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh-Hwa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yu","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara Soria","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-098X","authenticated-orcid":false,"given":"Mogens","family":"Bernsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Billan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-7218","authenticated-orcid":false,"given":"John","family":"Kaczmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Grose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-2222","authenticated-orcid":false,"given":"Michael J.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor Eliade","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Dutcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere E.","family":"Okpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-6354","authenticated-orcid":false,"given":"Guoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Bidadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Gumuscu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.116824_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116824_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.oraloncology.2018.07.005","article-title":"Clinical outcomes with therapies for previously treated recurrent\/metastatic head-and-neck squamous cell carcinoma (R\/M HNSCC): a systematic literature review","volume":"84","author":"Lala","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2026.116824_bib3","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-0073","article-title":"INTERLINK-1: a phase III, randomized, placebo-controlled study of Monalizumab plus Cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma","author":"Fayette","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.116824_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2026.116824_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10167","key":"10.1016\/j.ejca.2026.116824_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejca.2026.116824_bib7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116824_bib8","unstructured":"Merck & Co I. KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use. Rahway, NJ: 153; 2024."},{"issue":"10212","key":"10.1016\/j.ejca.2026.116824_bib9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejca.2026.116824_bib10","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116824_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.ejca.2026.116824_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116824_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000535154","article-title":"A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: extended analysis of study 116","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2026.116824_bib14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase Ib\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116824_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejca.2026.116824_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2020-0937","article-title":"The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors","volume":"17","author":"Taylor","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2026.116824_bib17","unstructured":"Licitra L., Tahara M., Harrington K., Hurtado de Mendoza M.O., Guo Y., Aksoy S., et al. Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. J Clin Oncol 0(0):JCO-25-00570."},{"issue":"4","key":"10.1016\/j.ejca.2026.116824_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","article-title":"Randomized phase 3 LEAP-012 Study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment","volume":"45","author":"Llovet","year":"2022","journal-title":"Cardiovasc Interv Radiol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116824_bib19","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2025.43.16_suppl.4095","article-title":"LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma","volume":"43","author":"Finn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116824_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116824_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116824_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2009.23.8584","article-title":"Phase II Study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01","volume":"28","author":"Machiels","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116824_bib23","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/hed.26772","article-title":"Bleeding complications in patients with squamous cell carcinoma of the head and neck","volume":"43","author":"Bergamini","year":"2021","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.ejca.2026.116824_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2026.116824_bib25","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1200\/JCO.2024.42.16_suppl.6031","article-title":"Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116824_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Souli\u00e8res","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116824_bib27","unstructured":"Adlai Nortye announces topline results of phase III BURAN trial evaluating Buparlisib (AN2025) in combination with Paclitaxel for recurrent or metastatic HNSCC [press release]. \u3008https:\/\/ir.adlainortye.com\/news-releases\/news-release-details\/adlai-nortye-announces-topline-results-phase-iii-buran-trial\u3009. Accessed March 20, 2026."},{"issue":"22","key":"10.1016\/j.ejca.2026.116824_bib28","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.22.01994","article-title":"Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, recurrent\/metastatic head and neck cancer","volume":"41","author":"Bauman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2026.116824_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6115","article-title":"FIERCE-HN: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF\/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R\/M) HPV negative head and neck squamous cell carcinoma (HNSCC)","volume":"43","author":"Bauman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116824_bib30","series-title":"Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial","first-page":"S1554","author":"Le Tourneau","year":"2024"},{"key":"10.1016\/j.ejca.2026.116824_bib31","unstructured":"Merus announces first patient dosed in LiGeR-HN2, a phase 3 trial evaluating petosemtamab in 2\/3L r\/m HNSCC [press release]. \u3008https:\/\/ir.merus.nl\/news-releases\/news-release-details\/merus-announces-first-patient-dosed-liger-hn2-phase-3-trial\u3009. Accessed March 20, 2026."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:43:06Z","timestamp":1783485786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0959804926006052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116824","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib plus pembrolizumab versus standard of care in recurrent\/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116824"}}